Results 51 to 60 of about 32,890 (266)

Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. [PDF]

PLoS ONE, 2012
Ustekinumab is a fully human IgG1κ monoclonal antibody targeting interleukin (IL)-12/23 p40 subunit. The role of IL-12/23-mediated pathway in the mechanism of various inflammatory disorders especially psoriasis has been well recognized. Recently the long-
Kenshiro Tsuda, Keiichi Yamanaka, Makoto Kondo, Kimiko Matsubara, Ryogen Sasaki, Hidekazu Tomimoto, Esteban C Gabazza, Hitoshi Mizutani   +7 more
doaj   +1 more source

Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn’s Disease: An Experience of 2 IBD Centers

Inflammatory Bowel Diseases, 2023
Background Ustekinumab (UST), a human monoclonal antibody that binds the p40 subunit of interleukin 12 (IL-12) and IL-23, is licensed for induction and maintenance therapy of moderate to severe inflammatory bowel disease (IBD).
C. McDonald, H. Kerr, E. Gibbons, Tincymol Lukose, D. Cheriyan, G. Harewood, S. Patchett, A. O'Toole, O. Kelly, K. Boland   +9 more
semanticscholar   +1 more source

Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review [version 2; peer review: 2 approved]

F1000Research, 2021
Background: Ustekinumab is a monoclonal antibody that inhibits interleukins 12 and 23. It is approved for treatment of Crohn’s disease (CD) in adults; however, there is a paucity of data regarding its use in pediatric CD. We describe our experience using
Phinga Do, John Andersen, Ashish Patel, Gaith Semrin, Luis Sifuentes-Dominguez, Phuong Luu, Bhaskar Gurram   +6 more
doaj   +1 more source

Ustekinumab [PDF]

Reactions Weekly, 2021
  +5 more sources

Structural basis of IL-23 antagonism by an Alphabody protein scaffold [PDF]

, 2014
Protein scaffolds can provide a promising alternative to antibodies for various biomedical and biotechnological applications, including therapeutics.
Bloch, Yehudi, Deroo, Sabrina, Desmet, Johan, Devreese, Bart, Henderikx, Paula, Hettmann, Thore, Lasters, Ignace, Lorent, Eric, Loverix, Stefan, Savvides, Savvas, Somers, Klaartje, Vandenbroucke, Karen, Verstraete, Kenneth, Wen, Yurong   +13 more
core   +1 more source

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis

Journal of Crohn's & Colitis
Background and Aims Previously published long-term safety data reported a favourable ustekinumab safety profile for the treatment of inflammatory bowel disease [IBD].
Subrata Ghosh, B. Feagan, E. Ott, C. Gasink, B. Godwin, C. Marano, Y. Miao, Tony Ma, E. Loftus, W. Sandborn, S. Danese, M. Abreu, Bruce E. Sands   +12 more
semanticscholar   +1 more source

Pharmacokinetic Similarity of ABP 654, an Ustekinumab Biosimilar Candidate: Results from a Randomized, Double‐blind Study in Healthy Subjects

Clinical pharmacology in drug development, 2023
ABP 654 is a proposed biosimilar to ustekinumab reference product (RP) which works through antagonism of interleukin‐12 and interleukin‐23. Ustekinumab RP is used for the treatment of chronic inflammatory conditions, including some forms of plaque ...
V. Chow, D. Mytych, Shyamal Das, J. Franklin   +3 more
semanticscholar   +1 more source

Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis

Nature Communications
Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a life-threatening autoimmune disease that often results in kidney failure caused by crescentic glomerulonephritis (GN).
Jonas Engeßer, Robin Khatri, Darius P. Schaub, Yu Zhao, H. Paust, Zeba Sultana, N. Asada, J. Riedel, Varshi Sivayoganathan, Anett Peters, A. Kaffke, S. Jauch-Speer, Thiago Goldbeck-Strieder, Victor G. Puelles, Ulrich O. Wenzel, Oliver M. Steinmetz, Elion Hoxha, J. Turner, H. Mittrücker, T. Wiech, T. Huber, Stefan Bonn, Christian F. Krebs, U. Panzer   +23 more
semanticscholar   +1 more source

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary [PDF]

, 2018
K
Balázs, Tamás, Borsi, András, Gyulai, Rolland, Holló, Péter, Kemény, Lajos V., Károlyi, Zsuzsánna, Kárpáti, Sarolta, Pogácsás, Lilla, Rakonczai, Pál, Remenyik, Éva, Szegedi, Andrea, Takács, Péter, Wikonkál, Norbert   +12 more
core   +1 more source

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

BioDrugs, 2023
Background CT-P43 is a candidate ustekinumab biosimilar in clinical development. Objectives This paper aims to demonstrate equivalent efficacy of CT-P43 to originator ustekinumab in adults with moderate to severe plaque psoriasis.
K. Papp, Mark G. Lebwohl, D. Thaçi, J. Jaworski, B. Kwiek, J. Trefler, A. Dudek, J. Szepietowski, N. Reznichenko, J. Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, K. Bartnicka-Maslowska, A. Reich, Yuriy Andrashko, Sunghyun Kim, Y. Bae, D. Jeon, Jinsun Jung, HyunSeung Lee, T.N. Pyo, Woo-Sick Ko   +22 more
semanticscholar   +1 more source